Article
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Cancer - 1 Jan 2015
Tung Nadine, Battelli Chiara, Allen Brian, Kaldate Rajesh, Bhatnagar Satish, Bowles Karla, Timms Kirsten, Garber Judy E, Herold Christina, Ellisen Leif, Krejdovsky Jill, DeLeonardis Kim, Sedgwick Kristin, Soltis Kathleen, Roa Benjamin, Wenstrup Richard J, Hartman Anne-Renee
Abstract excerpt
BACKGROUND: Next-generation sequencing (NGS) allows for simultaneous sequencing of multiple cancer susceptibility genes and, for an individual, may be more efficient and less expensive than sequential testing. The authors assessed the frequency of deleterious germline mutations among individuals with breast cancer who were referred for BRCA1 and BRCA2 (BRCA1/2) gene testing using a panel of 25 genes associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.